Cmax is out of the range [Study As­sess­ment]

posted by Mikalai  – Belarus, 2018-08-01 14:05 (2056 d 20:03 ago) – Posting: # 19121
Views: 4,564

Dear all,
We recently conducted a BE trial. It was a classical 2-period, 2-sequence study of a drug that consists of a combination of two active substances. Unfortunately, results one of analytes, a parent drug, fell sightly outside of the 80-125% range, below 80% for Cmax. CV was below 30% and post-hoc power was less than 80% for this analyte. Are there any ways we can defend bioequivalence without conducting another BE trail? All other analytes fell within 80-125%. Specifically, what should we put in the protocol or in a supporting letter to justify our lower border of CI around 79% for Cmax?

Complete thread:

UA Flag
Activity
 Admin contact
22,940 posts in 4,812 threads, 1,639 registered users;
39 visitors (0 registered, 39 guests [including 7 identified bots]).
Forum time: 09:09 CET (Europe/Vienna)

Those people who think they know everything
are a great annoyance to those of us who do.    Isaac Asimov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5